Literature DB >> 31742534

MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017.

Elmoubasher Farag, Reina S Sikkema, Ahmed A Mohamedani, Erwin de Bruin, Bas B Oude Munnink, Felicity Chandler, Robert Kohl, Anne van der Linden, Nisreen M A Okba, Bart L Haagmans, Judith M A van den Brand, Asia Mohamed Elhaj, Adam D Abakar, Bakri Y M Nour, Ahmed M Mohamed, Bader Eldeen Alwaseela, Husna Ahmed, Mohd Mohd Alhajri, Marion Koopmans, Chantal Reusken, Samira Hamid Abd Elrahman.   

Abstract

We tested samples collected from camels, camel workers, and other animals in Sudan and Qatar in 2015 and 2017 for evidence of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. MERS-CoV antibodies were abundant in Sudan camels, but we found no evidence of MERS-CoV infection in camel workers, other livestock, or bats.

Entities:  

Keywords:  Camelus; Middle East respiratory syndrome coronavirus; One Health; PCR; Qatar; S1 protein; Sudan; bats; camel handlers; camels; coronavirus; humans; live animal market; livestock; public health; serology; seropositive; veterinary medicine; viruses; zoonoses

Mesh:

Substances:

Year:  2019        PMID: 31742534      PMCID: PMC6874263          DOI: 10.3201/eid2512.190882

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus from camels that can cause serious respiratory disease and death in humans (). Camel populations across the Middle East and Africa are highly seropositive. However, the only known human cases of clinical MERS-CoV infection in Africa were related to travel from Qatar and Saudi Arabia (https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/RRA_MERS-CoV_7th_update.pdf), and serologic evidence for infections in humans resulting from camel exposure in Africa is limited (). The only published report of MERS-CoV circulation in camels in Sudan involved the testing of camel samples from 1983; that study found a seroprevalence of 82% (49/60) (). Two publications from Egypt describe evidence of possible MERS-CoV circulation in Sudan, reporting a seroprevalence of 91% (543/594) in camels originating from Sudan and a seroprevalence of 92% (48/52), combined with a reverse transcription PCR positivity rate of 5.6%, in camels originating from Ethiopia and Sudan (). Neither study presented conclusive evidence for MERS-CoV circulation in Sudan. Here, we provide the results of a study conducted in the Butana region of Al Gezira, Sudan, to investigate the local point prevalence of MERS-CoV and MERS-CoV antibodies among camel handlers, camels, and other animals in 2015 and 2017. We also report the results of a MERS-CoV screening in camels from Sudan sampled in Qatar directly upon importation. We collected samples from humans and animals at a live animal market, an outdoor slaughter area adjacent to that market, and the Tamboul Camel Research Centre (TCRC), all located in Tamboul, Sudan. Overall, ≈1,660 camels and additional other livestock are usually present at the animal market; these camels come from individual small farms, where they are largely kept under free-roaming conditions. At the TCRC, ≈100 camels are generally present and kept out of contact with other camels. Before their arrival at the TCRC, they were herded on the Butana Plain. We also collected samples from 90 Sudan camels that were imported into Qatar in 2015. After arriving at the Hamad International Airport in Doha, Qatar, these camels were directly transported to the Al Shahaniya animal market in Doha. We sampled them immediately after their arrival. We stored all samples locally (1–1.5 years in Sudan, 1 month in Qatar) and tested them after shipment to the Netherlands. We tested 56 human, 190 camel, 3 bat, 14 donkey, 15 cow, 15 sheep, and 15 goat serum samples for antibodies against MERS-CoV spike S1 using the protein microarray technique (). We performed a virus neutralization test and a spike S1 protein–based ELISA (human serum samples only) to confirm the detection of MERS-CoV antibodies by protein microarray (). In confirmatory tests, we included equal numbers of negative serum samples of the same species, when available. We considered samples positive if results of all tests were positive (protein microarray cutoff 1:20, 50% plaque-reduction neutralization titer cutoff 1:20, ELISA cutoff optical density 0.5). To resolve problems with possible mislabeling, we tested all animal serum samples collected in 2017 with a cytochrome B gene PCR to confirm species origins (). We tested camel nasal (n = 168), nasopharyngeal (n = 24), and rectal (n = 61) swab specimens and milk (n = 33), urine (n = 30), and fecal (n = 42) samples for MERS-CoV RNA using a reverse transcription PCR targeting the upstream of envelope and nucleocapsid genes, as described previously (,). In addition, we tested legs of camel ticks (Hyalomma dromedarii) and bat (Tadarida spp.) tissues collected at the TCRC in 2015 for MERS-CoV RNA. In 2015, a total of 92% of camels in Sudan and 99% of camels exported to Qatar from Sudan were MERS-CoV seropositive (Table). In 2017, all camels tested in Sudan were seropositive. No MERS-CoV antibodies were found in human or bat serum samples or serum samples from livestock other than camels. MERS-CoV RNA was detected in the nasal swabs from 3 camels imported into Qatar in 2015 but in no other samples.
Table

MERS-CoV RNA and antibody positivity among humans, bats, camels, and other livestock, Sudan, 2015 and 2017*

Sample typeLocation of sample collection2015
2017
No. samplesMERS-CoV RNA, no. positive/total no. (%)MERS-CoV antibody, no. positive/total no. (%)No. samplesMERS-CoV RNA, no. positive/total no. (%)MERS-CoV antibody, no. positive/total no. (%)
Camel worker serum
Tamboul slaughter area3NTND35NTND
Tamboul market8NTNDNA
TCRC
7
NT
ND

3
NT
ND
Camel serum†
Tamboul slaughter area‡§4ND4/4 (100)13ND13/13 (100)
Tamboul marketद27ND26/27 (96)NA
TCRC¶31ND27/31 (87)25ND25/25 (100)
Qatar§¶#
90
ND
89/90 (99)

NA


Camel nasopharyngeal swabs†
TCRC¶
NA



24
ND
NT
Camel nasal swabs†
Tamboul slaughter area‡§11NDNTNA
Tamboul marketद11NDNTNA
TCRC¶31NDNT25NDNT
Qatar§¶#**
90
3/90 (3)
NT

NA


Camel ticks (Hyalomma dromedarii) from 25 camels
TCRC
155
ND
NT

NA


Other animal serum
CattleTamboul slaughter area6NDND9NTND
GoatTamboul slaughter area5NDND10NTND
SheepTamboul slaughter area5NDND10NTND
DonkeyTamboul slaughter area5NDND9NTND
Bat††
TCRC
3
ND
NT

NA


Bat tissue‡‡TCRC13NDNTNA

*MERS-CoV, Middle East respiratory syndrome coronavirus; NA, not available; ND, not detected; NT, not tested; TCRC, Tamboul Camel Research Centre.
†From camels >2 years of age.
‡Serum and swab samples received from the slaughter field and live animal market were not matched.
§Sample set included meat camels.
¶Sample set included milk camels.
#Sample set included race camels.
**Just imported into Qatar from Sudan.
††Genus unknown.
‡‡Tadarida spp.; lung, intestine, and brain tissues stored in formalin.

*MERS-CoV, Middle East respiratory syndrome coronavirus; NA, not available; ND, not detected; NT, not tested; TCRC, Tamboul Camel Research Centre.
†From camels >2 years of age.
‡Serum and swab samples received from the slaughter field and live animal market were not matched.
§Sample set included meat camels.
¶Sample set included milk camels.
#Sample set included race camels.
**Just imported into Qatar from Sudan.
††Genus unknown.
‡‡Tadarida spp.; lung, intestine, and brain tissues stored in formalin. The results of this study are in agreement with other seroepidemiologic studies performed in Africa. The camel population was highly seropositive for MERS-CoV, and none or a low percentage of nasal or nasopharyngeal swabs from camels were positive for MERS-CoV RNA. As shown before in other countries in Africa, human serum samples did not show neutralizing activity against MERS-CoV (). In 1 study in Kenya, 2 of 1,122 livestock handlers were found positive for MERS-CoV neutralizing antibodies (). Other livestock were also seronegative for MERS-CoV in our study, a finding in agreement with most serosurveys, although some sheep, goats, and donkeys and 1 cow have been reported to have MERS-CoV antibodies (,). The number of human and livestock samples tested was low in this investigation. Therefore, the results of this study are not conclusive. However, this study provides preliminary insight into MERS-CoV circulation in Sudan, the country with the third largest dromedary camel population in the world (http://www.fao.org/faostat/en/#data/QA). We show evidence of extensive MERS-CoV circulation in camels but no evidence of circulation in other livestock, bats, and humans.
  10 in total

1.  Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.

Authors:  V M Corman; M A Müller; U Costabel; J Timm; T Binger; B Meyer; P Kreher; E Lattwein; M Eschbach-Bludau; A Nitsche; T Bleicker; O Landt; B Schweiger; J F Drexler; A D Osterhaus; B L Haagmans; U Dittmer; F Bonin; T Wolff; C Drosten
Journal:  Euro Surveill       Date:  2012-12-06

2.  Dynamics of mitochondrial DNA evolution in animals: amplification and sequencing with conserved primers.

Authors:  T D Kocher; W K Thomas; A Meyer; S V Edwards; S Pääbo; F X Villablanca; A C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction.

Authors:  V M Corman; I Eckerle; T Bleicker; A Zaki; O Landt; M Eschbach-Bludau; S van Boheemen; R Gopal; M Ballhause; T M Bestebroer; D Muth; M A Müller; J F Drexler; M Zambon; A D Osterhaus; R M Fouchier; C Drosten
Journal:  Euro Surveill       Date:  2012-09-27

4.  Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review.

Authors:  R S Sikkema; E A B A Farag; Mazharul Islam; Muzzamil Atta; C B E M Reusken; Mohd M Al-Hajri; M P G Koopmans
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals.

Authors:  Ahmed Kandeil; Mokhtar Gomaa; Mahmoud Shehata; Ahmed El-Taweel; Ahmed E Kayed; Awatef Abiadh; Jamel Jrijer; Yassmin Moatasim; Omnia Kutkat; Ola Bagato; Sara Mahmoud; Ahmed Mostafa; Rabeh El-Shesheny; Ranawaka Apm Perera; Ronald Lw Ko; Nagla Hassan; Basma Elsokary; Lotfi Allal; Ahmed Saad; Heba Sobhy; Pamela P McKenzie; Richard J Webby; Malik Peiris; Mohamed A Ali; Ghazi Kayali
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

6.  Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections.

Authors:  Nisreen M A Okba; V Stalin Raj; Ivy Widjaja; Corine H GeurtsvanKessel; Erwin de Bruin; Felicity D Chandler; Wan Beom Park; Nam-Joong Kim; Elmoubasher A B A Farag; Mohammed Al-Hajri; Berend-Jan Bosch; Myoung-Don Oh; Marion P G Koopmans; Chantal B E M Reusken; Bart L Haagmans
Journal:  Emerg Infect Dis       Date:  2019-10-17       Impact factor: 6.883

7.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

Authors:  Chantal B E M Reusken; Bart L Haagmans; Marcel A Müller; Carlos Gutierrez; Gert-Jan Godeke; Benjamin Meyer; Doreen Muth; V Stalin Raj; Laura Smits-De Vries; Victor M Corman; Jan-Felix Drexler; Saskia L Smits; Yasmin E El Tahir; Rita De Sousa; Janko van Beek; Norbert Nowotny; Kees van Maanen; Ezequiel Hidalgo-Hermoso; Berend-Jan Bosch; Peter Rottier; Albert Osterhaus; Christian Gortázar-Schmidt; Christian Drosten; Marion P G Koopmans
Journal:  Lancet Infect Dis       Date:  2013-08-09       Impact factor: 25.071

8.  MERS-CoV Antibodies in Humans, Africa, 2013-2014.

Authors:  Anne Liljander; Benjamin Meyer; Joerg Jores; Marcel A Müller; Erik Lattwein; Ian Njeru; Bernard Bett; Christian Drosten; Victor Max Corman
Journal:  Emerg Infect Dis       Date:  2016-06-15       Impact factor: 6.883

9.  Lack of serological evidence of Middle East respiratory syndrome coronavirus infection in virus exposed camel abattoir workers in Nigeria, 2016.

Authors:  Ray Ty So; Ranawaka Apm Perera; Jamiu O Oladipo; Daniel Kw Chu; Sulyman A Kuranga; Kin-Ho Chan; Eric Hy Lau; Samuel Ms Cheng; Leo Lm Poon; Richard J Webby; Malik Peiris
Journal:  Euro Surveill       Date:  2018-08

Review 10.  Cross host transmission in the emergence of MERS coronavirus.

Authors:  Chantal Bem Reusken; V Stalin Raj; Marion P Koopmans; Bart L Haagmans
Journal:  Curr Opin Virol       Date:  2016-01-29       Impact factor: 7.090

  10 in total
  11 in total

1.  MERS-CoV in Africa-an enigma with relevance to COVID-19.

Authors:  Stanley Perlman; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2020-10-06       Impact factor: 25.071

Review 2.  Emergence of Bat-Related Betacoronaviruses: Hazard and Risks.

Authors:  Roger Frutos; Jordi Serra-Cobo; Lucile Pinault; Marc Lopez Roig; Christian A Devaux
Journal:  Front Microbiol       Date:  2021-03-15       Impact factor: 5.640

Review 3.  Pathology of Coronavirus Infections: A Review of Lesions in Animals in the One-Health Perspective.

Authors:  Valentina Zappulli; Silvia Ferro; Federico Bonsembiante; Ginevra Brocca; Alessandro Calore; Laura Cavicchioli; Cinzia Centelleghe; Giorgia Corazzola; Steffen De Vreese; Maria Elena Gelain; Sandro Mazzariol; Valentina Moccia; Nicolò Rensi; Alessandro Sammarco; Filippo Torrigiani; Ranieri Verin; Massimo Castagnaro
Journal:  Animals (Basel)       Date:  2020-12-11       Impact factor: 2.752

Review 4.  Unresolved questions in the zoonotic transmission of MERS.

Authors:  Malik Peiris; Stanley Perlman
Journal:  Curr Opin Virol       Date:  2022-01-06       Impact factor: 7.090

5.  MERS-CoV Confirmation among 6,873 suspected persons and relevant Epidemiologic and Clinical Features, Saudi Arabia - 2014 to 2019.

Authors:  Shahul H Ebrahim; Andrew D Maher; Udhayashankar Kanagasabai; Sarah H Alfaraj; Nojom A Alzahrani; Saleh A Alqahtani; Abdullah M Assiri; Ziad A Memish
Journal:  EClinicalMedicine       Date:  2021-11-14

6.  Outbreak of Middle East Respiratory Syndrome Coronavirus in Camels and Probable Spillover Infection to Humans in Kenya.

Authors:  Isaac Ngere; Elizabeth A Hunsperger; Suxiang Tong; Julius Oyugi; Walter Jaoko; Jennifer L Harcourt; Natalie J Thornburg; Harry Oyas; Mathew Muturi; Eric M Osoro; John Gachohi; Cynthia Ombok; Jeanette Dawa; Ying Tao; Jing Zhang; Lydia Mwasi; Caroline Ochieng; Athman Mwatondo; Boku Bodha; Daniel Langat; Amy Herman-Roloff; M Kariuki Njenga; Marc-Alain Widdowson; Peninah M Munyua
Journal:  Viruses       Date:  2022-08-09       Impact factor: 5.818

7.  Limited transmissibility of coronavirus (SARS-1, MERS, and SARS-2) in certain regions of Africa.

Authors:  Anwar E Ahmed
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693

8.  Coronavirus disease 2019 (COVID-19) outbreak: Could pigs be vectors for human infections?

Authors:  Tanja Opriessnig; Yao-Wei Huang
Journal:  Xenotransplantation       Date:  2020-03-28       Impact factor: 3.907

9.  A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.

Authors:  Barbara Schmidt; Ralf Wagner; David Peterhoff; Vivian Glück; Matthias Vogel; Philipp Schuster; Anja Schütz; Philip Neubert; Veruschka Albert; Stefanie Frisch; Mara Kiessling; Philip Pervan; Maren Werner; Nicole Ritter; Leon Babl; Maria Deichner; Frank Hanses; Matthias Lubnow; Thomas Müller; Dirk Lunz; Florian Hitzenbichler; Franz Audebert; Viola Hähnel; Robert Offner; Martina Müller; Stephan Schmid; Ralph Burkhardt; Thomas Glück; Michael Koller; Hans Helmut Niller; Bernhard Graf; Bernd Salzberger; Jürgen J Wenzel; Jonathan Jantsch; André Gessner
Journal:  Infection       Date:  2020-08-21       Impact factor: 7.455

Review 10.  The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy.

Authors:  Ranjan K Mohapatra; Lucia Pintilie; Venkataramana Kandi; Ashish K Sarangi; Debadutta Das; Raghaba Sahu; Lina Perekhoda
Journal:  Chem Biol Drug Des       Date:  2020-07-26       Impact factor: 2.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.